Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D O Calligaro

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
European Journal of Pharmacology|October 17, 1998
Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane F P Bymaster, H E Shannon, K Rasmussen, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activationP Sauerberg, L Jeppesen, P H Olesen, et al.
European Journal of Pharmacology|August 26, 2000
Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive miceT Rasmussen, P Sauerberg, E B Nielsen, et al.
Journal of Medicinal Chemistry|September 1, 1995
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacyclesJ S Ward, L Merritt, D O Calligaro, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1994
Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptorsH E Shannon, F P Bymaster, D O Calligaro, et al.
Journal of Medicinal Chemistry|October 23, 1998
Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activityP Sauerberg, L Jeppesen, P H Olesen, et al.
Pharmacology, Biochemistry, and Behavior|March 13, 2017
Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effectsJ M Witkin, J A Monn, J Li, et al.
Brain Research|June 12, 1998
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effectsF P Bymaster, P A Carter, S C Peters, et al.
Life Sciences|March 9, 1999
Potential role of muscarinic receptors in schizophreniaF P Bymaster, H E Shannon, K Rasmussen, et al.
Life Sciences|January 1, 1997
In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonistH E Shannon, D E Womer, F P Bymaster, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
European Journal of Pharmacology|October 17, 1998
Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane F P Bymaster, H E Shannon, K Rasmussen, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activationP Sauerberg, L Jeppesen, P H Olesen, et al.
European Journal of Pharmacology|August 26, 2000
Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive miceT Rasmussen, P Sauerberg, E B Nielsen, et al.
Journal of Medicinal Chemistry|September 1, 1995
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacyclesJ S Ward, L Merritt, D O Calligaro, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1994
Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptorsH E Shannon, F P Bymaster, D O Calligaro, et al.
Journal of Medicinal Chemistry|October 23, 1998
Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activityP Sauerberg, L Jeppesen, P H Olesen, et al.
Pharmacology, Biochemistry, and Behavior|March 13, 2017
Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effectsJ M Witkin, J A Monn, J Li, et al.
Brain Research|June 12, 1998
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effectsF P Bymaster, P A Carter, S C Peters, et al.
Life Sciences|March 9, 1999
Potential role of muscarinic receptors in schizophreniaF P Bymaster, H E Shannon, K Rasmussen, et al.
Life Sciences|January 1, 1997
In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonistH E Shannon, D E Womer, F P Bymaster, et al.
Pageof 5